Tissue Protrusion after DES: Adverse Events at Long Term?

Original Title: Tissue Protrusion after Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy.

Reference: Fuyu Qiu et al. J Am Coll Cardiol Intv. 2016;9(14):1499-1507.

 

DESAfter DES implantation we may observe tissue protrusion (plaque or thrombus) relatively often, especially in unstable lesions; however, its clinical impact has not been studied. The aim of this study was to assess long term prevalence and clinical impact of tissue protrusion after DES implantation.

The ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) prospectively included 8,663 patients undergoing DES stenting.

In a pre-specified intravascular ultrasound (IVUS) substudy, 2,072 patients had post stenting IVUS and were classified according to presence or absence of post stenting tissue protrusion.

After stenting, 34.3% of lesions showed tissue protrusion by IVUS. Maximum tissue protrusion was 0.7 mm2 in area (range 0.5 to 1.2 mm) and 3 mm in length (range 1.4 to 6.7 mm).

Patients with tissue protrusion were often undergoing high risk ACS (STEMI and NSTEMI) and less often unstable angina or stable ischemic cardiomyopathy.

In 893 lesions studied by IVUS prior stenting, tissue protrusion was associated with larger proximal reference lumen area, greater plaque burden, and more plaque ruptures, attenuated plaque, and VH-thin cap fibroatheromas.

Because tissue protrusion often lead to post-dilation, these patients had a larger lumen area than patients without tissue protrusion.

At two year follow up, there was less clinically driven target lesion revascularization in patients with tissue protrusion and no significant difference in incidence of major adverse cardiac events (cardiac death, MI, or stent thrombosis) in patients with vs without tissue protrusion.

Conclusion

Tissue protrusion diagnosed by IVUS after DES stenting is not associated to adverse events in the long term, partly because of greater post dilation stent expansion.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...